Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
- Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes onlyRR 2.11 [1.77, 2.52]6 studies · 4291 participantsHigh